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Rheumatic fever
prophylaxis in South Africa
- is bicillin 1,2 million
units every 4 weeks
appropriate?
E. D. Daniels, D. Mohanlal, J. M. Pettifor
Rheumatic fever is a major health problem in South Africa.
Although intramuscular benzathine penicillin (bicillin)
1,2 million units (MU) every 4 weeks is widely used for
secondary prophylaxis, studies in other countries have
shown a recurrence rate of 3 - 8% over 5 - 6 years in
patients on this regimen. It has been recommended that
serum penicillin concentrations should be maintained
above 0,02 mg/ml to prevent such recurrences. The World
Health Organisation (WHO) and the American Heart
Association have recommended since 1988 that patients
in high-risk areas for the development of rheumatic fever
should receive benzathine penicillin 1,2 MU every 3 weeks
rather than every 4.
The aims of this study were, firstly, to determine the
prevalence of serum penicillin concentrations below 0,02
j.Jg/ml in rheumatic fever patients on benzathine penicillin
1,2 MU 4-weekly and, secondly, to study the effect of
increasing the dose to 1,8 MU 4-weekly in patients with
subtherapeutic concentrations.
Forty-five of 51 rheumatic fever patients (88%) in this
study on benzathine penicillin 1,2 MU 4-weekly had low
serum penicillin concentrations « 0,02 j.Jg/ml) at the end of
the 4th week after the injection. Penicillin was detected in
the urine of 30 of the 45 patients (67%) with low
concentrations, suggesting that such patients have tissue-
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bound penicillin which might be important in preventing
rheumatic fever. The 15 patients (33%) with subtherapeutic
serum penicillin concentrations and no detectable
penicillin in the urine could be at very high risk for
recurrent attacks of rheumatic fever.
Fourteen of 29 patients (48%) given the higher dose of
benzathine penicillin (1,8 MU 4-weekly) had
subtherapeutic serum penicillin concentrations at the end
of the 4th week after the injection, but in all 29 penicillin
was detected in the urine.
Review of our present policy of secondary prophylaxis
for rheumatic fever is necessary. Concentrated
preparations of benzathine penicillin (600 000 Ulml) are
not available in South Africa; administration of a higher
dose (1,8 MU) 4-weekly would therefore require a double
injection, which could affect compliance adversely. We
recommend that rheumatic fever patients in our area
should receive benzathine penicillin 1,2 MU 3-weekly as
recommended by the WHO until strategies for secondary
prophylaxis have been evaluated further.
S Atr Med J 1994; 84: 477-481.
Rheumatic heart disease is the most common form of
acquired cardiac disease in children worldwide. The
prevalence of rheumatic fever and rheumatic heart disease
in schoolchildren has been estimated to be less than 1/1 000
in developed countries and 11 - 22/1 000 in developing
countries.' In 1972 McLaren et aJ.2 reported a prevalence of
rheumatic heart disease of 6,9/1 000 in 3 - 18-year-old
children in Soweto, Johannesburg. Edginton and Gear" list
rheumatic heart disease among the top 10 causes of death
in the 15 - 24-year age group in South Africa. The financial
burden on the country is reflected in the estimated costs
(approximately R40 million annually) for valve replacement
surgery at six major South African centres for the 5-year
period 1982 - 1987.'
Secondary antibiotic prophylaxis against group A
l3-haemolytic streptococcus (GABHS) infection in patients
with rheumatic heart disease will not only prevent
recurrences but will improve healing of carditis' Recurrent
attacks of rheumatic fever usually result from non-
compliance with prophylaxis. However, a disturbing
recurrence rate of 3 - 8% over 5 - 6 years has been
recorded in patients known to be compliant with the regimen
of intramuscular benzathine penicillin (bicillin) 1,2 million
units (MU) every 4 weeks.'-' Low as this rate may be, it is
unacceptable because these patients run the risk of
increased cardiac damage despite conscientiously arriving
every month (often at great inconvenience) for treatment
which is quite painful.
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Such 'prophylaxis failure' is thought to be associated with
low serum penicillin concentrations in the 4th week after the
injection.'·'o It has accordingly been recommended by the
World Health Organisation (WHO) and the American Heart
Association (AHA) that rheumatic fever patients in high-risk
areas should receive benzathine penicillin every 3 weeks.'-9.11
Some authors have even recommended injections every
2 weeks."
A potential disadvantage of giving benzathine penicillin
more frequently is the risk that compliance may decrease.
However, Lue et al.' found that changing from a 4-weekly to
a 3-weekly regimen did not affect compliance. To avoid the
potential problems arising from changing the frequency of
injections, Ayoub9has suggested that therapeutic serum
penicillin concentrations might be maintained on a 4-weekly
regimen if the dose were to be increased.
The present study was motivated by the recurrence of
rheumatic fever in a patient who had been on regular
secondary prophylaxis (benzathine penicillin 1,2 MU
4-weekly) at Coronation Hospital, Johannesburg.
The aims of the study were, firstly, to determine the
prevalence of subtherapeutic serum penicillin concentrations
in patients on benzathine penicillin 1,2 MU 4-weekly and,
secondly, to study the effect of increasing the dose to
1,8 MU 4-weekly in patients with subtherapeutic serum
penicillin concentrations.
Subjects and methods
The study population consisted of patients with confirmed
rheumatic fever and rheumatic heart disease as diagnosed
by the revised Jones Criteria (1988)13 who were being
followed up in the Johannesburg area.
Penicillin concentrations on benzathine
penicillin 1,2 MU
Consecutive patients were recruited over a 13-month period
at either Baragwanath Hospital or Coronation Hospital and
its related primary health care clinics. Patients were included
if they had received benzathine penicillin 1,2 MU 28 days
previously and were excluded if they had received any other
antibiotics during that month.
Informed written consent was obtained from the parents
of patients or from the patients themselves if they were older
than 14 years. The study was approved by the Committee
for Research on Human SUbjects, University of the
Witwatersrand.
Blood and random urine samples for penicillin assay were
collected from each patient, and their age, sex and weight
were recorded. All patients were then given benzathine
penicillin (Penilente 1,8 g; Novo) 1,2 MU and their usual
appointment date for 28 days later.
Blood samples were centrifuged and the serum separated
within an hour after sampling. The serum and urine were
then frozen at -20°C. Specimens were transported in
batches, frozen on ice, to the central laboratory of the
South African Institute for Medical Research (SAIMR) in
Johannesburg. All specimens reached the central laboratory
within 30 minutes.
Penicillin assays were performed using the agar diffusion
microbiological method as described by Sutherland and
Robinson. 14 Two replicate samples of each specimen were
placed randomly in wells in an agar plate impregnated with
the organism Sarcina lutea. Duplicate samples of five
different standard concentrations of penicillin were also
placed on each plate.
The plates were incubated overnight and the zones of
growth inhibition around each well were measured. A graph
was constructed by plotting the concentrations of each of
the standard penicillin solutions against their inhibition zones
on semi-logarithmic graph paper. The concentrations of
penicillin in the patients' specimens were then determined
from this graph.
Serum penicillin concentrations of 0,02 ~g/ml or higher
were defined as therapeutic and those lower than 0,02 ~g/ml
as subtherapeutic. This is an arbitrary therapeutic
concentration as used by Kaplan et al.' The limit of sensitivity
of the assay was 0,015 ~g/ml and concentrations lower than
0,015 ~g/ml were therefore defined as undetectable.
Serum creatinine levels were measured in all the
specimens with detectable serum penicillin concentrations
and were compared with serum creatinine levels measured
in a random sample of 16 specimens from patients with
undetectable serum penicillin concentrations. Urine
penicillin/creatinine ratios were calculated to correct for
varying volumes and concentrations of urine samples. An
assessment of the accuracy and repeatability of the assay
was made by analysis of the inhibition zones of the standard
penicillin solutions.
Since penicillin is known to degenerate in stored
specimens, even if they are frozen,'·'· the time interval
between collection of specimens and performance of the
assay was recorded for correlation with the penicillin
concentrations obtained. Furthermore, a trial was performed
to document the rate at which penicillin degenerates over a
12-week period in specimens stored at -20°C. Serum and
urine specimens were collected from 8 of the study patients.
These specimens were used to prepare six 0,5 ml aliquots of
serum and six 0,5 ml aliquots of urine for each patient. A
single aliquot of serum and a single aliquot of urine from
each patient were thawed at 2-weekly intervals and penicillin
concentrations were measured.
In order to assess the susceptibility of local strains of
GABHS to penicillin, a throat swab was taken from each
patient and forwarded in appropriate transport medium to
the local hospital laboratory for culture. Throat swabs were
also sent from non-rheumatic fever patients who presented
with follicular tonsillitis at the Paediatric Outpatient
Department at Coronation Hospital between July and
October 1990. A total of 16 positive cultures for GABHS
were obtained. Penicillin minimum inhibitory concentrations
(MICs) and minimum bactericidal concentrations (MBCs)
using the serial tube dilution method in 10% serum broth
were determined for these 16 cultures.
Penicillin concentrations on benzathine
penicillin 1,8 MU
Those patients who had subtherapeutic serum penicillin
concentrations on benzathine penicillin 1,2 MU were entered
into this part of the study. A dose of 1,8 MU was
administered to these patients at their return clinic visit.
Blood and urine samples were collected 28 days after
administration of the higher dose.
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therapeutic serum penicillin concentrations compared with
the 11 - 15-year-olds (3%) or those aged 16 years or older
(9%) (P < 0,05, Fisher's exact test). To eliminate the effect of
the large number of undetectable serum and urine penicillin
concentrations, the relationship between serum and urine
inhibition zones was tested but no correlation was found
(P> 0,05).
Urine penicillin/creatinine ratios did not correlate with the
age of the patient (r, = -0,09, P = 0,15), the weight of the
patient (r, = -0,32, P = 0,20) or the time which elapsed until
performance of the assay (r, =-0,33, P =0,13).
Penicillin concentrations on benzathine
penicillin 1,8 MU
Thirty of the 45 patients with subtherapeutic serum penicillin
concentrations on benzathine penicillin 1,2 MU were given
1,8 MU. One patient did not come back for follow-up. She
had been admitted with a recurrent attack of rheumatic fever
1 week after receiving benzathine penicillin 1,8 MU. The
analysis was therefore performed on the data for the
remaining 29 patients. There were 16 males and 13 females,
aged 12 ± 3 years.
Fifteen of the 29 patients (52%) had therapeutic serum
penicillin concentrations on bicillin benzathine penicillin 1,8
MU compared with only 6 of 51 (12%) on 1,2 MU (P < 0,001)
(Fig. 1). Penicillin was detected in the urine of all 29 patients
given 1,8 MU. The mean urine penicillin/creatinine ratio of
0,54 mg/lJmol on the 1,8 MU dose was significantly higher
than the ratio of 0,23 mg/lJmol for the same 29 patients on
1,2 MU (P < 0,005, paired t-test).
Penicillin concentrations on benzathine
penicillin 1,2 MU
The analysis was performed on the results of 51 patients
who had specimens collected exactly 28 days after
administration of 1,2 MU benzathine penicillin. There were
24 males and 27 females (mean age 13 ± 3 years). The
period between collection of specimens and performance of
the penicillin assay was 23 ± 17 days.
Subtherapeutic serum penicillin concentrations
« 0,02 IJg/ml) were found in 45 of the 51 patients (88%). All
but 1 of these 45 patients had undetectable serum penicillin
concentrations « 0,015 IJg/ml). The mean serum creatinine
concentration of the 6 patients with therapeutic serum
penicillin concentrations (~ 0,02 IJg/ml) was 50,0 ± 14,0
mmol/1. This value did not differ from the mean serum
creatinine value of 49,9 ± 10,4 IJmol/1 for a random sample
of 16 patients with subtherapeutic serum penicillin
concentrations (P = 0,77).
Penicillin was detected in the urine of 5 of the 6 patients
with therapeutic serum concentrations (83%) and in the
urine of 30 of the 45 patients with subtherapeutic serum
concentrations (67%) (Table I).
A minimum of 11 patients was required for this part of the
study to detect a difference of 0,02 IJg/ml in serum penicillin




Statistical analysis was performed using a SAS computer
package licensed to the University of the Witwatersrand.
Differences between means were assessed with Student's
Hest. Penicillin concentrations were not normally distributed
and were therefore analysed using non-parametric tests.
Differences between proportions were analysed with the
x'-test or Fisher's exact test where appropriate. Correlation
between variables was assessed by calculation of the
Spearman rank correlation coefficient (r.). Probability
P ~ 0,05 was defined as significant.
Table I. Relationship between serum and urine penicillin
concentrations on benzathine penicillin 1,2 MU (51 patients)
Fig. 1. Serum penicillin concentrations on benzathine penicillin
1,2 and 1,8 MU.
Urine conc. Serum conc. Serum cone. Total No.











Serum penicillin concentrations on benzathine penicillin
1,8 MU did not correlate with urine penicillin/creatinine
ratios (r, = 0,16, P = 0,20), the age of the patient (r, = 0,14,
P > 0,05), the weight of the patient (r, =0,05, P =0,05) or
the time interval between specimen collection and assay
(r, =0,64, P > 0,05).
Serum penicillin concentrations did not correlate with urine
penicillin/creatinine ratios (r, = 0,29, P = 0,17), the time
elapsed to performance of the assay (r, = -0,02, P = 0,15),
the weight of the patient (r, = 0,23, P = 0,18) or the age of
the patient (r, = -0,16, P = 0,15). However, a higher
proportion (36%) of patients aged 1°years or younger had
Throat culture results
Throat swab results were available for 44 of the study
patients. Results for the other 7 patients could not be
traced. GABHS was cultured from the throat swabs of 2
patients. Both were asymptomatic and were not treated on
antibiotics. Neither of them had a recurrence of rheumatic
fever on follow-up for 2 months after these results.
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Of the non-rheumatic fever patients with sore throats, 16
had throat swabs positive on culture for GABHS that were
forwarded for penicillin MIC/MBC determinations. The
MICs and MBCs were identical and ranged from 0,003 to
0,015 IJg/ml, and the MBC/MIC ratios for all the organisms
were equal to 1. Tolerance of the group A Streptococcus to
penicillin would be suggested by MBC/MIC ratios of 10 or
over."
Assessment of penicillin assay
Penicillin assays on the patients' serum and urine
specimens were performed on 11 different dates. An
analysis was made of the variability of the zones of inhibition
for the replicate samples of 69 serum and 119 urine
standard penicillin solutions used in these assays.
The inhibition zones of the serum standard solutions
ranged from 11,0 to 38,0 mm. The inhibition zones of
replicate samples from each standard solution differed by a
mean of 0,9 ± 1,0 mm (P = 0,46). There was also no
difference between the inhibition zones of the replicate
samples of the urine standard solutions (P = 0,65).
Rate of degeneration of penicillin in
stored specimens
Penicillin was detected in serum of 3 of the 8 patients, and
these results were consistent throughout the 84 days of the
trial. There was no difference between the mean urine
penicillin/creatinine ratio of 0,87 mg/lJmol for the specimens
assayed 14 days after collection and the mean ratio of
0,98 mg/lJmol for those assayed 84 days after collection
(P = 0,80).
Discussion
The role of antibiotic prophylaxis in the prevention of
rheumatic fever has been well established.'6,,, Penicillin
remains the most important therapeutic agent for both
primary and secondary prophylaxis of rheumatic fever.
Recurrences of rheumatic fever in patients known to be
compliant with benzathine penicillin 1,2 MU every 4 weeks
for secondary prophylaxis have led to doubts about the
usefulness of this regimen.
The majority of our patients (88%) had subtherapeutic
serum penicillin concentrations in the 4th week after
administration of benzathine penicillin 1,2 MU. Eighty-six
per cent of patients had undetectable serum concentrations
on this dose. These results are similar to those of Ginsburg
et al.,1. who reported subtherapeutic serum penicillin
concentrations « 0,02 IJg/ml) 18 days after doses of 0,6 MU
and 1,2 MU in all of 13 children aged 11 years and younger.
All these patients had undetectable serum penicillin
concentrations 30 days after administration of benzathine
penicillin. Kaplan et al. 7 also reported subtherapeutic serum
penicillin concentrations « 0,02 IJg/ml) in 64% of 193 serum
samples taken 28 days after administration of a 1,2 MU
dose. Penicillin was undetectable in 56% of these samples.
Ayoub9 has questioned the value of therapeutic serum
penicillin concentrations in the management of rheumatic
fever, since tissue-bound penicillin may be more important in
preventing streptococcal infection in the pharynx.
Nightingale" confirms that it is the quantity of antibiotic
present at the site of infection (called the critical antibiotic
concentration) that is important in killing infecting organisms
and that serum antibiotic MICs/MBCs do not necessarily
reflect such tissue concentrations. Konig et al. 20 noted that
antibiotics with small differences in MIC values had vastly
different bactericidal and bacteriostatic effects in vivo. They
suggest that clinical decisions based largely on MIC values
ignore the pharmacological properties of antibiotics and the
role of the host immune system in eliminating organisms.
Furthermore, sub-bactericidal concentrations of penicillin
have been shown to minimise streptococcal virulence by
inducing loss of the organism's hyaluronic acid capsule and
M-proteins'6.21 Rheumatogenic strains of GABHS tend to· be
highly virulent."·'6 It is therefore possible that serum penicillin
concentrations below the MBCs for GABHS might be
effective in secondary prophylaxis of rheumatic fever.
Ginsburg et al. '• found penicillin in the urine of all 13
patients with undetectable serum penicillin concentrations
30 days after being given benzathine penicillin 1,2 MU.
Urinary excretion of penicillin in these patients suggests that
there is penicillin in the tissues even though serum penicillin
is not measurable.'· Serum penicillin concentrations may
therefore be an inadequate measure not only of tissue-
bound penicillin but also of the risk for development of
rheumatic fever. Penicillin was not detected in the urine of
one-third of the patients in our study with subtherapeutic
serum penicillin concentrations on benzathine penicillin 1,2
MU. If absent urinary penicillin excretion represents lack of
tissue-bound penicillin, these patients must be considered to
be at very high risk for recurrent attacks of rheumatic fever.
Fifty-two per cent of patients given benzathine penicillin
1,8 MU had therapeutic serum penicillin concentrations, as
opposed to only 12% of patients given 1,2 MU. All the
patients who were given 1,8 MU had detectable penicillin
concentrations in the urine. This suggests that patients on
1,8 MU 4-weekly still have tissue-bound penicillin 28 days
post-injection. This higher dose may wel.l be adequate to
prevent rheumatic fever despite the high proportion of
patients with subtherapeutic serum penicillin concentrations.
Preparations of benzathine penicillin with concentrations of
600 000 Ulml12,22 would require a single injection of 3 ml to
administer 1,8 MU. Such preparations are not readily .
available in South Africa. The use of a double injection to
administer 1,8 MU, as was used in this study, is not feasible
for long-term prophylaxis because it may adversely affect
compliance.
One of the patients entered into the second part of the
study was admitted with a recurrent attack of rheumatic
fever 1 week after benzathine penicillin 1,8 MU was
administered. She had received 1,2 MU 4-weekly for at
least 6 months preceding this recurrence, Her clinical
presentation fulfilled both the 1982 and the more liberal
1988 revised Jones Criteria for a rheumatic fever recurrence.
She had no evidence of infective endocarditis on clinical or
echocardiographic examination. The patient was
hospitalised for 2 months and is now receiving benzathine
penicillin 1,2 MU 3-weekly.
In view of the documented prophylaxis failure in our study
population and the fact that a large number of patients
could be at high risk for recurrences of rheumatic fever, we
recommend that the regimen of benzathine penicillin 1,2 MU
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4-weekly used by our local hospitals and clinics be changed
to 1,2 MU 3-weekly as recommended by the WHO. This
latter regimen has been shown to protect against
recurrences in clinical trials. Further studies should be
performed to clarify which are the best antibiotic regimens
for secondary prophylaxis of rheumatic fever. The findings of
this study suggest that benzathine penicillin 1,8 MU
4-weekly may protect against recurrences even though
patients may not have therapeutic serum penicillin
concentrations. Such studies should include measurement
of both clinical and pharmacological parameters in the same
cohort of patients followed up for at least 5 years to
document recurrence rates.
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A randomised clinical trial
E. T. M. De Jonge, R. C. Pattinson, J. D. Makin,
C. P. Venter
Objective. To compare evacuation under systemic
analgesia (fentanyl and midazolam) in a treatment room
(ward group) with evacuation under general anaesthesia in
theatre.
Design. A prospective randomised clinical trial.
Setting. A tertiary medical centre serving a black urban
population.
Subjects. One hundred and forty-two patients with
uncomplicated incomplete abortions.
Intervention. Randomisation into two groups, those for
evacuation under systemic analgesia and those for
evacuation under general anaesthesia.
Main outcome measures. Both groups were compared
in terms of safety, efficacy, acceptability, blood
consumption and time delay between admission and
evacuation.
Results. Significantly less blood was used in the ward
group (37 units for 13 patients) than in the theatre group
(65 units for 24 patients) (P < 0,03). Significantly less time
was taken between admission and evacuation in the ward
group (median 7 hours 15 minutes) than in the theatre
group (median 12 hours 38 minutes) (P < 0,0003)..
Evacuation under fentanyl and midazolam was safe,
effective and acceptable for the majority of patients
compared with evacuation under general anaesthesia.
Conclusion. Patients with uncomplicated incomplete
abortions (uterine size equivalent to a pregnancy of 14
weeks' duration or less) can undergo evacuation safely
and effectively under fentanyl and midazolam and have a
significantly smaller chance of requiring a blood
transfusion.
S Atr Med J 1994; 84: 481-483.
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